Overview

This document presents findings regarding the Gal-9 antibody, HFB9, and its role in immune regulation and cancer therapy.

Mechanisms and Efficacy

• Gal-9 is implicated in immune suppression within the tumor microenvironment, affecting responses in patients with Acute Myeloid Leukemia (AML).
• Monoclonal antibodies targeting Gal-9 have shown sustained immunological responses.
• Evidence suggests these antibodies can potentially reverse immune suppression, making them significant for cancer therapy.

Experimental Results

• PBMCs from healthy donors were analyzed over 30 days, revealing distinct interactions with Gal-9 and 2-9 HFB.
• Binding affinity studies indicated a high level of reactivity between humanized anti-Gal-9 antibody and tumor expressions.
• Cytotoxic effects and efficacy were demonstrated in syngeneic tumor models after administration of HFB9-2.

Antitumor Activity

• In vivo evaluations showed the potential of HFB9-2 as an anti-tumor agent in various cancer models.
• Significant anti-tumor effects were observed with combinations of anti-Gal-9 treatments, achieving complete tumor rejection in a substantial percentage of tested subjects.

Conclusion

• The HFB9-2 neutralizing antibody demonstrated:
  • Sub-nanomolar affinity for Gal-9.
  • Cross-reactivity to mouse and monkey orthologs.
  • Favorable pharmacokinetics and developability.
  • Key inhibitory effects on Th1 apoptosis and Treg expansion.
• The observed levels of Gal-9 in AML patients suggest a potential therapeutic target to counter immunosuppression and enhance the efficacy of cancer treatments.

Contact Information

For additional inquiries or information regarding the study, please reach out via email to g.margallducos@hifibio.com.